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Inflammation has been associated with atherothrombotic stroke and recently with cardioembolic stroke. Different genetic risk
factors have been specifically associated with the subtypes of ischemic stroke (cardioembolic, atherothrombotic, and lacunar).
However, there are no studies that have generated genetic risk scores for the different subtypes of ischemic stroke using
polymorphisms associatedwith inflammation.Methods.Wehave analyzed 68 polymorphisms of 30 inflammatorymediator genes in
2,685 subjects: 1,987 stroke cases and 698 controls. We generated a genetic scoring system with the most significant polymorphisms
weighted by the odds ratio of every polymorphism and taken into consideration the stroke subtype. Results.Three polymorphisms,
rs1205 (CRP gene), rs1800779, and rs2257073 (NOS3 gene), were associated with cardioembolic stroke (𝑝 value < 0.05). The score
generatedwas only associatedwith the cardioembolic stroke subtype (𝑝 value: 0.001) andwas replicated in an independent cohort (𝑝
value: 0.017).The subjects with the highest score presented a cardioembolic stroke in 92.2% of the cases (𝑝 value: 0.002).Conclusion.
The genetics of inflammatorymarkers is more closely associated with cardioembolic strokes than with atherothrombotic or lacunar
strokes. The genetic risk scoring system could be useful in the prediction and differentiation of ischemic stroke; however, it might
be specific to particular ischemic stroke subtypes.
1. Introduction
Ischemic stroke is a leading cause of death and disability
worldwide [1]. Although twin and familial aggregation stud-
ies have revealed a significant genetic component involved in
the etiology of stroke, not all of the genetic risk factors respon-
sible for this heritability have been determined [2]. Classical
linkage analysis approaches have reported an association of
the PDE4D and ALOX5AP genes with ischemic stroke, but
replication of these findings has been inconsistent [3]. In
addition, candidate gene association studies have permitted
the identification of several other candidate genes that may
also be associated with ischemic stroke, such as APOE, IL6,
MTHFR, and TNF𝛼 [2]. However, these studies have proven
difficult to replicate for a number of reasons: it is because they
may be false positive associations; it is because of the fact that
each genemay only contribute partially to overall heritability;
or it is because the studies did not study the ischemic stroke
subtypes separately [4, 5].
Genome-wide association study (GWAS) approaches
have highlighted the relationship of unsuspected genes
with ischemic stroke subtypes. Cardioembolic stroke is an
ischemic stroke category that includes patients with arterial
occlusion processes presumably due to an embolus arising in
the heart mainly due to the presence of atrial fibrillation. Ath-
erothrombotic stroke or large vessel atherosclerosis is another
ischemic stroke subtype that comprises strokes with >50%
stenosis or occlusion of amajor brain artery or branch cortical
artery, presumably due to atherosclerosis. A meta-analysis
of GWAS on ischemic stroke identified the ZFHX3 gene on
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chromosome 16q22 as a locus specifically associated with
atrial fibrillation and cardioembolic stroke [6, 7]. Addition-
ally, another ischemic stroke-related GWAS showed intrigu-
ing results, including the identification of risk variants for
atrial fibrillation and cardioembolic stroke on chromosome
4q25 near the PITX2 gene [8] and for atherothrombotic
stroke in the 9p21 locus [9]. Furthermore, an association
between large vessel stroke and theHDAC9 gene on chromo-
some 7p21.1 was recently identified [10]. Notably, the associ-
ation of ischemic stroke with ZFHX3, PITX2, the 9p21 locus,
andHDAC9was verified in the collaborativeMETASTROKE
study in which these loci were found to be specific to
particular stroke subtypes [11].
Inflammatory proteinsmight therefore play an important
role in stroke occurrence. The changes to the atheromatous
plaques caused by inflammation mediators in atherothrom-
botic stroke are associated with vessel occlusion processes
and the subsequent development of this subtype of ischemic
stroke [12]. Intuitively, it seems that inflammation medi-
ators might be more involved in atherothrombotic stroke
compared to cardioembolic or lacunar stroke. However,
transcriptomic studies have revealed that inflammation could
also have an important role in cardioembolic stroke [13].
It has, therefore, become clear that genetic factors con-
tribute to the development of ischemic stroke and that differ-
ent genes are involved in the different subtypes of ischemic
stroke and they only contribute partially to overall heritabil-
ity. We hypothesize that most of the genetic studies failed to
demonstrate true associations as they did not test ischemic
stroke subtypes separately and as they did not take into
account the fact that the risk polymorphisms only explain a
small part of the ischemic stroke risk.
Our aim is to separately evaluate the genes associated
with inflammation processes in the three main ischemic
stroke subtypes and to combine the risk polymorphisms into
a genetic scoring system in order to evaluate the value of
inflammation mediator gene polymorphisms in diagnostic
prediction.
2. Methods
2.1. Study Population. Our discovery cohort and our repli-
cation cohort consisted of consecutive Caucasian patients
with an ischemic stroke that were admitted to the emergency
room of a university hospital. Healthy controls for both
cohorts were recruited at the same hospital and were free
of ischemic stroke episodes, myocardial infarction, or other
cardiovascular diseases.
The discovery cohort (𝑛 = 1,612; 1,456 ischemic stroke
cases and 156 controls) was recruited between July 2005 and
May 2009. The replication cohort (𝑛 = 1,073; 531 ischemic
stroke cases and 542 controls) was recruited betweenNovem-
ber 2000 and May 2005 in a university hospital and the full
clinical protocol has previously been published [14].
Etiological stroke subgroups were determined according
to the Trial of Org 10172 in Acute Stroke Treatment (TOAST)
criteria [15]. In the discovery cohort, 374 ischemic strokes
were cardioembolic, 301 were atherothrombotic (large ves-
sel stroke), 226 were lacunar, and 555 were undetermined
ischemic stroke subtypes. In the replication cohort, 242
ischemic strokes were cardioembolic, 113 were atherothrom-
botic, and 176 were lacunar or undetermined ischemic stroke
subtypes. Patient information regarding established risk fac-
tors, including male gender, smoking, hypertension, diabetes
mellitus, and dyslipidemia, was collected. Also, written
informed consent was obtained from all subjects, who were
all of White European ancestry. In addition, the local ethics
committees approved the study.
2.2. Genetic Analysis. We identified 68 single nucleotide pol-
ymorphisms (SNPs) in 30 genes selected from the literature
related to inflammatory pathways associated with stroke
(Table 1).
The most relevant candidate genes were selected by man-
ual searching in Pubmed using the keywords “stroke AND
inflammation” or “inflammation” for phenotypes and the
keywords “polymorphism, SNP, mutation, variant” for poly-
morphisms. Only articles in English or Spanish were read.
Among candidate genes, SNP selection was performed
depending onprevious literature (themost studied SNPs) and
their functional effect, including thosewith an already known
modification in transcription, translation, or protein activity
or a hypotheticalmodification based on an amino acid substi-
tution. Whenever an interesting polymorphism involved
more than a single nucleotide change a SNP in perfect linkage
disequilibrium was chosen for genotyping.
In addition, we analyzed the whole gene region of the
IL6,MMP9, and NOS3 genes with tag SNPs using data from
the Hapmap project (http://hapmap.ncbi.nlm.nih.gov/). We
selected the SNPs using theTagger computer program in pair-
wise mode, MAF > 0.1 (minor allele frequency), and linkage
disequilibrium 𝑟2 > 0.8 andwith central European population
settings.
Genotyping was carried out at CEGEN (Barcelona,
Spain), using SNPlex technology (Applied Biosystems, Fos-
ter City, California) and GeneMapper 3.5 as the allele-
calling algorithm. For quality control, two HapMap samples
(NA10860 and NA10861) were included, and their genotype
concordancewas verified using SNPator (http://www.snpator
.org/). All the 68 SNPs achieved the minimum call rate.
2.3. Statistical Analysis and Score Generation. Sample size
calculation was performed using Ene 2.0 software (Servei
d’Estadı´stica Aplicada, UAB, Barcelona, http://sct.uab.cat/
estadistica/content/programari-d%27interes). A total of 110
subjects were needed in order to detect SNP frequencies
<0.30 in the experimental group (ischemic stroke patients)
and <0.15 in the reference group (healthy controls) with a
statistical power of 80% and 𝑝 value = 0.05.
Statistical analysis was performed using SPSS software,
v.15 (IBM, Chicago, Illinois). Statistical significance for each
SNP in the discovery cohort was assessed by chi-square
analysis or Fisher’s exact test.
Continuous variables were compared by analysis of vari-
ance (ANOVA) or Mann-Whitney or Kruskal-Wallis tests.
We generated a predictive score based on logistic regres-
sion (LR) and odds ratio (OR) coefficients, using forward
stepwise procedure, with a 𝑝 value of 0.05 as the threshold
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Table 1: List of polymorphisms and SNPs analyzed.
Gene SNP Chromosome
CD40 rs1883832 20
CRP rs1130864 1
CRP rs1205 1
CRP rs1800947 1
IFNG rs2430561 12
IL10 rs1800872 1
IL10 rs1800896 1
IL13 rs1295686 5
IL1A rs1800587 2
IL1B rs1143627 2
IL1B rs1143634 2
IL1B rs16944 2
IL4R rs1801275 16
IL4R rs1805015 16
IL5 rs2069812 5
IL5RA rs2290608 3
IL6 rs1800795 7
IL6 rs1800796 7
IL6 rs1800797 7
IL9 rs2069885 5
ITGA2 rs1126643 5
MCP1 rs1024611 17
MMP1 rs1799750 11
MMP10 rs486055 11
MMP12 rs2276109 11
MMP13 rs2252070 11
MMP2 rs243864 16
MMP3 rs3025058 11
MMP7 rs11568818 11
MMP8 rs1320632 11
MMP9 rs2236416 20
MMP9 rs2250889 20
MMP9 rs2274755 20
MMP9 rs2274756 20
MMP9 rs3787268 20
MMP9 rs3918241 20
MMP9 rs3918248 20
MMP9 rs3918253 20
MMP9 rs3918256 20
MMP9 rs3918278 20
MMP9 rs8113877 20
NOS2A rs1137933 17
NOS3 rs10266564 7
NOS3 rs10275136 7
NOS3 rs12703116 7
NOS3 rs1800779 7
NOS3 rs2070744 7
NOS3 rs2243428 7
Table 1: Continued.
Gene SNP Chromosome
NOS3 rs2257073 7
NOS3 rs2257090 7
NOS3 rs2288649 7
NOS3 rs2435608 7
NOS3 rs2435609 7
NOS3 rs2487151 7
NOS3 rs310584 7
NOS3 rs310585 7
NOS3 rs310586 7
NOS3 rs310588 7
NOS3 rs310589 7
NOS3 rs310590 7
NOS3 rs4722204 7
NOS3 rs6952465 7
SELE rs5355 1
SELE rs5361 1
SELP rs6133 1
TIMP1 rs2070584 23
TNF rs1800629 6
TNFRSF1B rs1061622 1
SNP: single nucleotide polymorphism.
for entry as previously described [14]. Afterwards, to establish
clinically relevant cut-off values, we automatically categorized
this score into risk groupswith themathematic algorithmchi-
squared Automatic Interaction Detector (CHAID), included
in SPSS.
3. Results and Discussion
3.1. Results. The study included a total of 2,685 subjects. The
discovery cohort included 1,456 ischemic stroke cases and
156 controls and the replication cohort included 531 ischemic
stroke cases and 542 controls. In terms of theTOAST etiology,
in the discovery cohort, 374 ischemic strokes were cardioem-
bolic, 301 were atherothrombotic (large vessel stroke), 226
were lacunar, and 555 were undetermined ischemic stroke
subtypes. In the replication cohort, 242 ischemic strokes
were cardioembolic, 113 were atherothrombotic, and 176 were
lacunar or undetermined ischemic stroke subtypes.
No SNPs were found to be associated with atherothrom-
botic stroke or lacunar stroke after statistical analyses on
the discovery cohort. Three SNPs were associated with
cardioembolic stroke following a dominant/recessive genetic
model (Table 3).
The SNP rs1205 was located in the untranslated region
(UTR) of the C-reactive protein (CRP) gene region and
SNPs rs1800779 and rs2257073 in the nitric oxide synthase-
3 (NOS3) gene region. When we selected the cardioem-
bolic stroke patients with atrial fibrillation before stroke
onset (46.4%), the three SNPs remained associated with
cardioembolic stroke with the exception of rs1205 (CC-
cases: 40.1%, CC-controls: 51.3%; 𝑝 value = 0.052), rs1800779
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Table 2: Clinical risk factors analyzed in the discovery and replication cohorts.
Discovery cases Discovery controls
𝑝 value Replication cases Replication controls 𝑝 value
(𝑛 = 374) (𝑛 = 156) (𝑛 = 242) (𝑛 = 547)
Male 50.4% (188) 28.5% (37) 1.4 × 10−05 47.5% (115) 42.5% (230) 0.19
Female 49.6% (185) 71.5% (93) 1.4 × 10−05 52.5% (127) 57.5% (311) 0.19
Presence of hypertension 63.1% (231) 40% (52) 4.7 × 10−06 59.8% (143) 44.2% (239) 5.5 × 10−05
Current smoker 13.8% (49) 14.6% (19) 0.77 18.3% (43) 12.6% (68) 0.036
Presence of diabetes mellitus 22% (80) 14.6% (19) 0.07 19.9% (48) 8.2% (44) 2.7 × 10−06
Presence of dyslipidemia 34.6% (125) 27.7% (36) 0.15 25.8% (62) 28.7% (155) 0.41
The significant results are in bold.
(GG-cases: 22.7%, GG-controls: 11.6%; 𝑝 value = 0.033), and
rs2257073 (TT-cases: 4.3%, TT-controls: 10.5%; 𝑝 value =
0.042).
Using the OR of the risk factors’ genotypes (Table 3) we
generated a genetic risk score for cardioembolic stroke:
Genetic risk score: (1.5 × rs1205CT/TT)
+ (2.2 × rs1800779GG)
+ (2.1 × rs2257073CT/CC) .
(1)
This score was associated with the risk of cardioembolic
stroke in the discovery cohort (cases: 3.4 points; controls: 2.9
points; 𝑝 value = 0.001). The genetic score was validated in
the replication cohort with the cardioembolic stroke group
(cases: 3.5 points; controls: 3.08 points; 𝑝 value = 0.017).
However, this score was not associated with the risk of
atherothrombotic stroke (𝑝 value = 0.24) or lacunar stroke (𝑝
value = 0.7). Interestingly, we observed similar results in the
undetermined stroke group compared to the cardioembolic
stroke cases (cases: 3.3 points; controls: 3.08 points; 𝑝 value =
0.07), although the results were not significant.
Hypertension and sex were the only clinical risk factors
associated with cardioembolic stroke (Table 2). When we
included these variables in the score, the association with
cardioembolic stroke was even more significant (cases: 7.6
points; controls: 6.6 points; 𝑝 value = 8.3 × 10−05) and this
was replicated in the replication cohort (cases: 5.1 points;
controls: 4.2 points; 𝑝 value = 0.002). However, for these two
clinical variables the score was also significantly associated
with atherothrombotic stroke (cases: 6.1 points; controls: 4.2
points; 𝑝 value = 0.003) and undetermined stroke (cases: 5.1
points; controls: 4.2 points; 𝑝 value = 0.025), although it was
not associated with lacunar stroke (𝑝 value = 0.31).
Using theCHAIDmethod implemented by SPSS software
we obtained three different risk groups for cardioembolic
stroke and controls depending on the genetic risk score that
we generated: a low risk group (score from 0 to 1.5 points), a
medium risk group (from 1.6 to 4.3 points), and a high risk
group (from 4.4 to 5.8 points). When we classified patients
and controls using this classification, 92% of the high risk
group presented a cardioembolic stroke (low risk: 50% of
subjects with cardioembolic stroke, medium risk: 74.1% of
subjects with cardioembolic stroke, and high risk: 92%of sub-
jects with cardioembolic stroke; 𝑝 value = 0.002) (Figure 1).
Low risk Medium risk High risk
Discovery
cohort
Replication
cohort
0–1.5 1.6–4.3 4.4–5.8
50% (n = 10) 74.1% (n = 235) 92.1% (n = 35)
16.7% (n = 3) 26.9% (n = 70) 33.3% (n = 11)
Figure 1: Cardioembolic risk groups based on genetic risk score
results. The percentage indicates the percentage of subjects inside
the group that presented a cardioembolic stroke.
3.2. Discussion. We aimed to combine risk polymorphisms
into a genetic scoring system in order to evaluate the diagnos-
tic prediction of polymorphisms of inflammatory mediator
genes for ischemic stroke subtypes.
In addition, we aimed to study the role of inflammatory
genes in ischemic stroke subtypes in order to establish which
ischemic stroke subtype is most greatly influenced by the
genetic background of the inflammatory mediator genes.
We generated a genetic risk scoring system for three
polymorphisms associated with cardioembolic stroke. The
genetic risk score was weighted by the OR of every genotype
and was validated in an independent replication cohort. The
genetic risk score was not associated with atherothrombotic
stroke or with lacunar stroke, the other subtypes of ischemic
stroke. Interestingly, we found a trend of association with
undetermined stroke. We hypothesize that the trend of
association between the score and undetermined stroke is
due to a high percentage of undetermined strokes that are
in fact cardioembolic strokes that have not been correctly
diagnosed. When we generated a new score combining
clinical risk factors (sex and hypertension) with genetic risk
factors, we observed that this new clinical-genetic score was
associated with the cardioembolic stroke subtype in both the
discovery and replication cohorts. However, this score was
also associatedwith atherothrombotic stroke. Ischemic stroke
subtypes have different genetic risk factors, and we observed
that the inclusion of sex and hypertension introduces a
confusing factor that reduces the accuracy of the genetic
score. The use of these genetic scores could be very useful in
the clinical practice to categorize the patients with atrial fib-
rillation. The genetic scores could detect those patients with
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the highest risk of suffering a future cardioembolic stroke and
consequently initiate a treatment with anticoagulants.
The polymorphisms and inflammatory mediator genes
analyzed in this study were only associated with the car-
dioembolic stroke subtype. This is very interesting as inflam-
mation has been classically more closely linked to atheroscle-
rotic processes than to cardioembolism. During the last few
years evidence has been found supporting the hypothesis
that inflammation plays a key role in cardioembolic stroke
and atrial fibrillation, the main risk factor for cardioembolic
stroke [16]. Interestingly when we selected the cardioembolic
stroke patients with atrial fibrillation before the stroke, the
three SNPs of CRP and NOS3 were still associated with
cardioembolic stroke, with very similar results compared to
the whole group of cardioembolic stroke patients, indicating
an association of these genetic markers with cardioembolic
stroke patients with atrial fibrillation and without atrial
fibrillation. Moreover, previous transcriptomic studies using
blood samples found inflammatorymediator genes played an
important role in cardioembolic stroke [13]. Our study found
that, in terms of genetics, inflammation also plays a key role
in cardioembolic stroke.
The NOS3 gene codes for nitric oxide synthase (NOS),
an enzyme that synthesizes nitric oxide (NO) from L-
arginine. NO is a reactive free radical that acts as a biological
mediator in several processes, including the migration or
proliferation of endothelial cells, platelet aggregation, and
leukocyte adhesion. NOS can regulate blood pressure by the
synthesis of NO, and it can also regulate metalloproteinase-2
(MMP2) andmetalloproteinase-9 (MMP9), which have been
associated with angiogenesis and inflammatory processes.
In fact, inhibition of NOS increases MMP2 activity [17–
19]. Our study found that the rs1800779 GG genotype and
the C carriers of the rs2257073 SNP were associated with
a higher risk of cardioembolic stroke. The rs2257073 SNP
was a tag SNP; however, the rs1800779 SNP of NOS3 has
been associated with an inhibition of the enzyme’s activity,
causing a decrease in NO production, and it has also been
associated with the presence of leukoaraiosis by a previous
paper [20]. The GG genotype was associated with a higher
risk of leukoaraiosis (a rarefaction of the brain white matter).
Interestingly, leukoaraiosis has been associated with inflam-
mation, hypertension, and blood brain-barrier disruption.
C-reactive protein (CRP) is a marker of systemic inflam-
mation that is significantly associated with an increased risk
of cardiovascular disease in the general population. CRP
has previously been associated with cardioembolic ischemic
stroke. Terruzzi et al. [21] studied 648 stroke patients with
a first documented cerebral infarction and they measured
CRP within the first 6 hours after onset and the CRP levels
were then stratified in quartiles.The results showed that CRP
quartiles weremostly increased in cardioembolic strokes; this
suggests that, in the acute phase of the cerebral infarction,
CRP might be a marker of cardioembolism [21]. Another
prospective study evaluated a cohort of 2,084 Japanese
ischemic stroke patients admitted in the first 7 days of onset;
the authors of the study showed that CRP is an independent
risk factor in the recurrence of cardioembolic ischemic stroke
during the first year after symptom onset [22].
4. Conclusions
In summary, we observed that polymorphisms of inflam-
matory mediator genes were more closely associated with
cardioembolic stroke than with other subtypes of ischemic
stroke including atherothrombotic stroke. In addition, we
generated a genetic risk scoring system to predict the risk
of cardioembolic stroke, which we also validated in an inde-
pendent population. The implementation of genetic scoring
systems can be useful in clinical practice to facilitate the
prediction of the risk of stroke in healthy people; however,
further studies are needed to confirm these results.
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